Consensus UCB Deutsche Boerse AG

Stocks

UNC

BE0003739530

Pharmaceuticals

Real-time Estimate Tradegate 04:16:10 23/09/2026 pm IST			5-day change	1st Jan Change
214.05 ^EUR	+1.01%		+2.05%	-9.02%

11/09	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
10/09	UCB: A rare window of affordability

Evolution of the Average Target: UCB

Data source: UCB(UCB)

Evolution of the Target Price: UCB

Data source: UCB(UCB)

Changes in Analyst Recommendations: UCB

Data source: UCB(UCB)

db96281.xqoWxNWHIdCtEXe-f3EmMjyJhzRsaOqYfQtivdHVPkM.iuQgsZS-borZZyPhFD5HbXX5zHNUMrPhFkkDxICRUCeFniL0vuJM6NR0Ng~ff78976ca8e576babad0363be1f20b3a

Analysts' recommendations: UCB

11/09	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
10/09	UCB: A rare window of affordability
20/08	Cancer vaccines finally garner the spotlight
18/08	UCB: An unimpressive upgrade-led correction opens a rare opportunity
11/08	Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed	MT
11/08	UCB barely moves despite positive calls from ING and Berenberg
31/07	AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT	MT
30/07	Kempen Upgrades UCB to Buy Rating, Boosts PT	MT
14/07	Where would AI lead Pharma in the long run?
03/07	Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals	MT
22/06	UBS Trims UCB's PT, Affirms Buy Rating	MT
15/06	UCB Slumps Following Analyst Downgrade
15/06	Barclays Downgrades UCB to Equalweight, Trims PT	MT
15/06	UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum	MT
09/06	UCB Favored by Oddo BHF
05/06	KBC Securities Maintains Buy Rating on UCB
21/05	UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum	MT
20/05	UCB: Executing well, but valuation lacks safety net
27/04	AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT	MT
30/03	MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says	MT
16/03	Berenberg says Belgian drugmaker UCB stock is undervalued
16/03	Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts	MT
26/02	UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot
24/02	Wolfe Research Kicks Off UCB Coverage at Outperform	MT
02/02	UCB on Track for 'Impressive' Growth Acceleration, Says RBC	MT

More recommendations

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
UCB	-	-	-	-
REGENERON PHARMACEUTICALS, INC.				+5.65%
MODERNA, INC.				-34.51%
CSL LIMITED				-1.68%
SAMSUNG BIOLOGICS CO.,LTD.				+41.81%
UCB				+33.49%
BIOGEN INC.				+5.69%
INCYTE CORPORATION				+0.64%
INNOVENT BIOLOGICS, INC.				+25.53%
SWEDISH ORPHAN BIOVITRUM AB				+11.76%
Average				+9.82%
Weighted average by Cap.				+5.79%